Benzinga | Jan 24, 2022 07:52AM EST

Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $142

Morgan Stanley analyst Matthew Harrison maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $124 to $142.